JP2016537966A5 - - Google Patents

Info

Publication number

JP2016537966A5

JP2016537966A5 JP2016521332A JP2016521332A JP2016537966A5 JP 2016537966 A5 JP2016537966 A5 JP 2016537966A5 JP 2016521332 A JP2016521332 A JP 2016521332A JP 2016521332 A JP2016521332 A JP 2016521332A JP 2016537966 A5 JP2016537966 A5 JP 2016537966A5

Authority

JP

Japan

Prior art keywords

bispecific molecule

domain

molecule according

seq

sequence

Prior art date

2014-10-10

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 13
• 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 13
• 125000006850 spacer group Chemical group 0.000 claims description 12
• 208000021161 Plasma cell disease Diseases 0.000 claims description 9
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 8
• 108010065323 Tumor Necrosis Factor Ligand Superfamily Member 13 Proteins 0.000 claims description 8
• 150000007523 nucleic acids Chemical group 0.000 claims description 8
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
• 238000000034 method Methods 0.000 claims description 5
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 4
• 208000034578 Multiple myelomas Diseases 0.000 claims description 4
• 208000007452 Plasmacytoma Diseases 0.000 claims description 4
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 4
• 210000004027 cell Anatomy 0.000 claims description 4
• 210000000988 bone and bone Anatomy 0.000 claims description 3
• 239000003814 drug Substances 0.000 claims description 3
• 238000004519 manufacturing process Methods 0.000 claims description 3
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
• 102000016611 Proteoglycans Human genes 0.000 claims description 2
• 108010067787 Proteoglycans Proteins 0.000 claims description 2
• 239000000654 additive Substances 0.000 claims description 2
• 230000000996 additive effect Effects 0.000 claims description 2
• 206010002022 amyloidosis Diseases 0.000 claims description 2
• 239000003085 diluting agent Substances 0.000 claims description 2
• 239000003937 drug carrier Substances 0.000 claims description 2
• 201000006569 extramedullary plasmacytoma Diseases 0.000 claims description 2
• 208000025750 heavy chain disease Diseases 0.000 claims description 2
• 201000000564 macroglobulinemia Diseases 0.000 claims description 2
• 239000008194 pharmaceutical composition Substances 0.000 claims description 2
• 208000031223 plasma cell leukemia Diseases 0.000 claims description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
• 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims description 2
• 239000013638 trimer Substances 0.000 claims description 2
• 239000000203 mixture Substances 0.000 claims 4
• 206010053869 POEMS syndrome Diseases 0.000 claims 1
• 230000003213 activating effect Effects 0.000 claims 1
• 238000012258 culturing Methods 0.000 claims 1
• 201000009234 osteosclerotic myeloma Diseases 0.000 claims 1
• 230000006044 T cell activation Effects 0.000 description 2
• 208000034189 Sclerosis Diseases 0.000 description 1
• 229940079593 drug Drugs 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• 230000001225 therapeutic effect Effects 0.000 description 1